Product Information

CAS No.	211448-85-0
Product Name	Denufosol

Biological Targets

P2RY2

Associated Conditions

retinal detachment·cystic fibrosis·macular retinal edema·Rhinitis, Allergic, Perennial

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

American journal of respiratory and critical care medicine • Vol. 176, Issue 4 • 2007

PMID: 17446337 DOI: 10.1164/rccm.200608-1238OC

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

The Journal of pharmacology and experimental therapeutics • Vol. 302, Issue 3 • 2002

PMID: 12183642 DOI: 10.1124/jpet.102.035485

The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Investigative ophthalmology & visual science • Vol. 43, Issue 11 • 2002

PMID: 12407168

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Advanced drug delivery reviews • Vol. 54, Issue 11 • 2002

PMID: 12458155 DOI: 10.1016/s0169-409x(02)00154-0

Denufosol

CAS No.	211448-85-0
MDL No.	N/A
MF	C₁₈H₂₇N₅O₂₁P₄
MW	773.30
InChI Key	FPNPSEMJLALQSA-MIYUEGBISA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	211448-85-0
Product Name	Denufosol

Biological Targets

P2RY2

Associated Conditions

retinal detachment·cystic fibrosis·macular retinal edema·Rhinitis, Allergic, Perennial

* The information provided here is compiled from public sources and is for reference only.

Denufosol

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Denufosol

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Denufosol

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Similar Products

Denufosol Tetrasodium

Denufosol

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis.

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

The P2Y(2) receptor agonist INS37217 stimulates RPE fluid transport in vitro and retinal reattachment in rat.

Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease.

Similar Products

Denufosol Tetrasodium

Documentation